{ "schemaVersion": 2, "eyebrow": "Infectious Diseases", "title": "Clostridioides difficile Treatment Selection", "summary": "Select therapy after confirming clinically compatible toxin-mediated disease, classify nonfulminant versus fulminant illness, favor fidaxomicin when feasible, use vancomycin when access or severity dictates, and add recurrence-prevention strategies for patients with prior episodes or high-risk features.", "seoDescription": "Physician guide to selecting fidaxomicin, vancomycin, fulminant CDI therapy, bezlotoxumab, and microbiota-based treatment for recurrent infection.", "clinicalQuestion": "How should clinicians select antimicrobial and recurrence-prevention therapy for initial, recurrent, and fulminant Clostridioides difficile infection?", "specialty": "Infectious Diseases", "audience": "U.S. physicians and medical trainees", "tags": [ "Clostridioides difficile infection", "CDI treatment", "fidaxomicin", "oral vancomycin", "bezlotoxumab", "recurrent CDI", "fulminant CDI", "fecal microbiota transplantation" ], "keyTakeaways": [ "For an initial nonfulminant CDI episode, IDSA/SHEA conditionally prefers fidaxomicin over vancomycin because it improves sustained response through lower recurrence; vancomycin remains an acceptable alternative when resources limit fidaxomicin use.[17][20]", "Use oral or nasogastric vancomycin 500 mg four times daily—not fidaxomicin—for fulminant CDI; add intravenous metronidazole 500 mg every 8 hours and consider rectal vancomycin when ileus impairs colonic drug delivery.[17][18]", "For a first recurrence, fidaxomicin is preferred when feasible; vancomycin taper-and-pulse remains a practical alternative, particularly for patients with multiple recurrences.[17]", "After at least two recurrences, move beyond repeated standard antibiotic courses: use an antibiotic regimen followed by microbiota restoration, including conventional FMT or FDA-approved fecal microbiota-based therapies where available.[13][15][18]", "Treat a positive assay only in the appropriate clinical context: NAAT-positive/toxin-EIA-negative results can represent toxigenic carriage and require clinical adjudication rather than automatic therapy.[4]" ], "sections": [ { "id": "confirm-disease-and-triage-severity", "eyebrow": "First decision", "heading": "Confirm CDI and identify fulminant disease before choosing therapy", "intro": "Treatment selection depends on clinical disease, assay interpretation, and immediate severity assessment.", "paragraphs": [ "Test and treat patients with clinically compatible diarrheal illness rather than a positive molecular result alone. CDI requires compatible manifestations plus stool evidence of a toxigenic strain and toxin activity; NAAT detects toxin genes, whereas toxin enzyme immunoassay (EIA) detects stool toxin. Multistep algorithms using GDH and toxin EIA, arbitrated by NAAT, improve interpretation over a standalone assay.[3][4][24]", "A NAAT-positive or GDH-positive/toxin-EIA-negative result is indeterminate for treatment selection: it may reflect low-level toxin below EIA detection in true CDI or asymptomatic toxigenic carriage. A third-stage NAAT, GDH, or toxigenic culture can address an apparent false-positive screening result but does not distinguish carriage from active CDI; reassess stool frequency, competing causes of diarrhea, systemic findings, and trajectory before prescribing CDI-directed antibiotics.[4]", "Classify nonsevere disease using WBC no greater than 15,000 cells/mL and serum creatinine below 1.5 mg/dL. Fulminant CDI is defined by hypotension or shock, ileus, or megacolon and requires immediate high-dose vancomycin-based therapy rather than the usual fidaxomicin-versus-vancomycin selection pathway.[2][17]" ], "bullets": [ "Stop the implicated antibacterial agent when clinically safe; this is a core early intervention alongside CDI-directed treatment.[1]", "Hospitalize patients with systemic symptoms or organ dysfunction; outpatient treatment is reserved for patients without either feature.[1]", "Do not use a toxin-negative molecular result as an automatic mandate to treat; document the clinical rationale if treatment is chosen despite discordance.[4]" ], "subsections": [], "table": { "caption": "Diagnostic and severity findings that change the immediate CDI treatment pathway.[2][4][17]", "columns": [ "Finding", "Interpretation", "Treatment consequence" ], "rows": [ [ "NAAT positive or GDH positive plus toxin EIA positive", "Supports toxin-mediated CDI in a symptomatic patient.[4]", "Select therapy by episode number and severity.[17]" ], [ "NAAT positive or GDH positive plus toxin EIA negative", "Could be active CDI with toxin below detection or toxigenic carriage.[4]", "Reassess clinical probability and alternative diarrhea etiologies before treatment.[4]" ], [ "WBC ≤15,000 cells/mL and creatinine <1.5 mg/dL", "Laboratory pattern supporting nonsevere disease.[2]", "Use a standard nonfulminant regimen.[2][17]" ], [ "Hypotension, shock, ileus, or megacolon", "Fulminant CDI.[17]", "Begin high-dose oral or NG vancomycin plus IV metronidazole; add rectal vancomycin for ileus.[17][18]" ] ] } }, { "id": "initial-nonfulminant-episode", "eyebrow": "Initial episode", "heading": "Choose fidaxomicin or vancomycin for initial nonfulminant CDI", "intro": "For nonfulminant disease, recurrence prevention drives first-line agent selection.", "paragraphs": [ "For an initial nonfulminant episode, select oral fidaxomicin when available and affordable because IDSA/SHEA conditionally prefers it over vancomycin based on improved sustained clinical response. The advantage is reduced recurrence, not a demonstrated difference in initial cure, mortality, or adverse events; therefore oral vancomycin is an appropriate alternative when access, coverage, discharge logistics, or formulary restrictions preclude fidaxomicin.[17][20]", "Use a 10-day course of fidaxomicin or oral vancomycin for initial nonfulminant CDI. Metronidazole is no longer preferred and should be reserved for settings in which fidaxomicin and vancomycin are unavailable.[2][7][17]", "Give particular weight to sustained response when recurrence would carry disproportionate consequences, such as a prior CDI history or a patient in whom further microbiome disruption would be especially consequential. Recurrence after an initial episode occurs in up to 25% of patients within 2 to 8 weeks after antibiotic treatment, and recurrence probability rises after each episode.[7]" ], "bullets": [ "Fidaxomicin: preferred IDSA/SHEA option for initial nonfulminant CDI when resources permit.[17]", "Oral vancomycin: acceptable initial nonfulminant alternative; use it when fidaxomicin is not feasible.[17][20]", "Metronidazole: use only when first-line agents cannot be accessed.[2]" ], "subsections": [], "table": { "caption": "Initial nonfulminant CDI regimen selection.[2][17][20]", "columns": [ "Option", "When to select", "Key tradeoff" ], "rows": [ [ "Fidaxomicin for 10 days", "Preferred for initial nonfulminant CDI when available.[2][17]", "Higher sustained response through lower recurrence; cost and access can limit use.[17][20]" ], [ "Oral vancomycin for 10 days", "Use when fidaxomicin is unavailable, unaffordable, or impractical.[2][17]", "Acceptable initial clinical response but less favorable recurrence outcome than fidaxomicin.[17][20]" ], [ "Metronidazole", "Reserve for limited-access settings where fidaxomicin and vancomycin are unavailable.[2]", "Deprioritized because first-line alternatives are preferred.[2][7]" ] ] } }, { "id": "fulminant-cdi", "eyebrow": "Emergency pathway", "heading": "Treat fulminant CDI with high-dose vancomycin-based combination therapy", "intro": "Do not extrapolate fidaxomicin recommendations to hypotension, shock, ileus, or megacolon.", "paragraphs": [ "For fulminant CDI, administer vancomycin 500 mg orally or by nasogastric tube four times daily and add intravenous metronidazole 500 mg every 8 hours. IDSA/SHEA continues to recommend vancomycin rather than fidaxomicin in this setting because fulminant disease was excluded from the trials supporting fidaxomicin.[17][18]", "If ileus is present, add rectal vancomycin retention enemas every 6 hours because oral or nasogastric delivery may not reliably reach the colon. Manage fulminant disease in a setting capable of intensive monitoring, and obtain early surgical consultation while medical therapy is initiated because fulminant CDI can progress rapidly.[13][18]", "The immediate objective is not recurrence optimization but restoration of perfusion, colonic drug exposure, and control of systemic toxicity. Reassess hemodynamics, abdominal examination, ileus, and evidence of megacolon serially; persistent deterioration despite appropriate combination therapy should trigger urgent escalation rather than substitution with routine nonfulminant regimens.[17][18]" ], "bullets": [ "Vancomycin 500 mg PO or NG four times daily is the IDSA/SHEA fulminant regimen.[17]", "Add metronidazole 500 mg IV every 8 hours.[18]", "With ileus, add rectal vancomycin every 6 hours as retention enemas.[18]", "Seek surgical input early in fulminant CDI while continuing antimicrobial therapy.[13][18]" ], "subsections": [], "table": { "caption": "Fulminant CDI regimen and delivery modifications.[17][18]", "columns": [ "Clinical circumstance", "CDI-directed treatment", "Operational action" ], "rows": [ [ "Fulminant CDI without ileus", "Vancomycin 500 mg PO or NG four times daily plus metronidazole 500 mg IV every 8 hours.[17][18]", "Monitor in a high-acuity setting and involve surgery early.[13][18]" ], [ "Fulminant CDI with ileus", "Add rectal vancomycin retention enemas every 6 hours to oral or NG vancomycin plus IV metronidazole.[18]", "Do not rely on enteral delivery alone when ileus may limit colonic exposure.[18]" ] ] } }, { "id": "recurrent-cdi", "eyebrow": "Recurrence prevention", "heading": "Escalate therapy after recurrence rather than repeating the same short course", "intro": "Episode number and recurrence risk determine whether to use antibiotics alone, adjunctive antibody, or microbiota restoration.", "paragraphs": [ "For a first recurrence, prefer fidaxomicin over a standard vancomycin course when feasible. Vancomycin remains effective for initial clinical cure, and an extended tapered-and-pulsed vancomycin regimen is an accepted alternative, especially where fidaxomicin access is constrained or in patients with multiple recurrences.[17][20]", "Consider a single intravenous dose of bezlotoxumab as adjunctive recurrence prevention in patients with a CDI recurrence within the prior 6 months. It is a monoclonal antibody against toxin B and is used with—not instead of—an active CDI antibiotic regimen; select it for patients in whom preventing another episode has high clinical value.[13][18]", "For second or subsequent recurrence, avoid cycling indefinitely through standard 10-day antibiotic courses. Options include fidaxomicin, tapered-and-pulsed vancomycin, or vancomycin followed by rifaximin 400 mg orally every 8 hours for 20 days; after appropriate antibiotic treatment for at least two recurrences, proceed to fecal microbiota transplantation or another microbiota-based recurrence-prevention strategy.[18]" ], "bullets": [ "First recurrence: fidaxomicin is preferred when feasible; tapered-and-pulsed vancomycin is an accepted alternative.[17]", "Recurrence within 6 months: consider adjunctive single-dose IV bezlotoxumab.[18]", "Second or subsequent recurrence: plan microbiota restoration after antibiotic treatment rather than relying solely on repeated standard courses.[13][18]", "FDA-approved fecal microbiota-based products, including fecal microbiota live-jslm and fecal microbiota spores live-brpk, are additional U.S. recurrence-prevention options.[15]" ], "subsections": [ { "heading": "Selecting microbiota restoration", "paragraphs": [ "Conventional FMT has high reported effectiveness in multiply recurrent CDI, with one expert review citing success greater than 85% compared with 40% to 50% for antibiotics in that setting. Current U.S. practice also includes FDA-approved fecal microbiota-based therapies, expanding options beyond conventional donor-stool FMT.[13][15]" ], "bullets": [ "Use microbiota restoration after antibiotic treatment for recurrent CDI, not as a substitute for acute control of fulminant disease.[13][18]", "Choose between conventional FMT and available FDA-approved microbiota-based products according to local expertise, product access, route, and patient-specific risk assessment.[1][15]" ] } ], "table": { "caption": "Episode-based selection for recurrent CDI.[13][17][18]", "columns": [ "Episode pattern", "Preferred or accepted treatment options", "Prevention escalation" ], "rows": [ [ "First recurrence", "Fidaxomicin preferred; tapered-and-pulsed vancomycin is an alternative.[17]", "Consider single-dose IV bezlotoxumab when recurrence occurred within 6 months.[18]" ], [ "Second or subsequent recurrence", "Fidaxomicin, tapered-and-pulsed vancomycin, or vancomycin followed by rifaximin 400 mg PO every 8 hours for 20 days.[18]", "After appropriate antibiotics for at least two recurrences, use FMT or another microbiota restoration strategy.[13][18]" ], [ "Multiply recurrent CDI", "Treat the active episode with an effective CDI antibiotic regimen.[13][18]", "Prioritize microbiota restoration; FMT success has been reported at greater than 85% in this setting.[13]" ] ] } }, { "id": "implementation-and-follow-up", "eyebrow": "Practical management", "heading": "Use treatment response and recurrence timing to guide follow-up", "intro": "The therapeutic endpoint is sustained clinical response, not simply completion of an antibiotic prescription.", "paragraphs": [ "At treatment initiation, discontinue the inciting antimicrobial when possible and review ongoing acid-suppressive therapy because antibiotic stewardship and discontinuation of chronic acid suppression are identified prevention and management measures. When the non-CDI antibacterial cannot be stopped, document the indication and narrow or shorten it whenever clinically safe.[1][16]", "Assess clinical response during therapy by stool frequency, systemic status, volume needs, abdominal findings, WBC, and creatinine rather than using repeat stool assays as a surrogate for cure. For initial and recurrent nonfulminant disease, the key comparative endpoint favoring fidaxomicin is sustained response at 4 weeks for initial CDI and at 30 days in recurrent CDI; cure, mortality, and adverse-event rates were comparable with vancomycin in pooled analyses.[20]", "A return of compatible diarrhea 2 to 8 weeks after therapy should prompt reassessment for recurrence, because this is the usual reported recurrence window after an initial treated episode. Repeat multistep testing only in a patient with recurrent symptoms compatible with CDI; then select therapy according to whether this is the first versus subsequent recurrence and whether the patient has progressed to fulminant illness.[7][24]" ], "bullets": [ "Stop or narrow non-CDI antibacterials whenever clinically safe.[1]", "Review chronic acid suppression as a modifiable management factor.[16]", "For recurrent compatible symptoms, re-enter the diagnostic and severity pathway rather than empirically repeating a prior regimen.[4][17]" ], "subsections": [], "table": { "caption": "Follow-up actions that change subsequent CDI treatment decisions.[7][17][20]", "columns": [ "Follow-up finding", "Interpretation", "Next action" ], "rows": [ [ "Clinical improvement during treatment", "Supports active response; sustained response is the relevant longer-term endpoint.[20]", "Complete the selected regimen and minimize modifiable recurrence drivers.[1][16]" ], [ "Compatible diarrhea returns 2-8 weeks after treatment", "Consistent with the reported post-treatment recurrence window.[7]", "Reassess with a multistep diagnostic approach and classify as first or subsequent recurrence.[4][17]" ], [ "Hypotension, shock, ileus, or megacolon develops at any episode number", "Signals fulminant CDI rather than routine recurrence management.[17]", "Switch immediately to high-dose vancomycin plus IV metronidazole; add rectal vancomycin if ileus is present.[17][18]" ] ] } } ], "faq": [], "references": [ { "number": 1, "title": "Clostridioides difficile-associated disease - Management Approach | BMJ Best Practice", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-gb/230/management-approach", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com" }, { "number": 2, "title": "Clostridioides difficile-associated disease - Treatment algorithm | BMJ Best Practice", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-gb/230/treatment-algorithm", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com" }, { "number": 3, "title": "Discordant Clostridioides difficile diagnostic assay and treatment ...", "detail": "bmjopen.bmj.com", "url": "https://bmjopen.bmj.com/content/bmjopen/10/9/e036342.full.pdf", "authors": "bmjopen.bmj.com", "host": "bmjopen.bmj.com" }, { "number": 4, "title": "Discordant Clostridioides difficile diagnostic assay and treatment practice: a cross-sectional study in a tertiary care hospital, Geneva, Switzerland | BMJ Open", "detail": "bmjopen.bmj.com", "url": "https://bmjopen.bmj.com/content/10/9/e036342", "authors": "bmjopen.bmj.com", "host": "bmjopen.bmj.com" }, { "number": 5, "title": "Discordant Clostridioides difficile diagnostic assay and ... - BMJ Open", "detail": "bmjopen.bmj.com", "url": "https://bmjopen.bmj.com/content/10/9/e036342.reviewer-comments", "authors": "bmjopen.bmj.com", "host": "bmjopen.bmj.com" }, { "number": 6, "title": "Effective treatment of Clostridioides difficile infection improves survival and affects graft-versus-host disease: a multicenter study by the Polish Adult Leukemia Group | Scientific Reports", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41598-024-56336-3", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 7, "title": "Experimental glycopeptide antibiotic EVG7 prevents recurrent Clostridioides difficile infection by sparing members of the Lachnospiraceae family | Nature Communications", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41467-025-64067-w", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 8, "title": "Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of Clostridioides difficile infection - An observational cohort study", "detail": "www.cell.com", "url": "https://www.cell.com/heliyon/fulltext/S2405-8440(24)06773-2", "authors": "www.cell.com", "host": "www.cell.com" }, { "number": 9, "title": "Experimental human colonisation with non-toxigenic Clostridioides difficile: a placebo-controlled randomised clinical trial | Nature Communications", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41467-026-74327-y", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 10, "title": "Plasmid-mediated metronidazole resistance in Clostridioides difficile | Nature Communications", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41467-020-14382-1", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 11, "title": "Retrospective Assessment of Guideline Adherence and Treatment Outcomes From Clostridioides difficile Infection Following the IDSA 2021 Clinical Guideline Update: Clostridioides difficile Infection | Open Forum Infectious Diseases | Oxford Academic", "detail": "academic.oup.com", "url": "https://academic.oup.com/ofid/article/11/10/ofae524/7758543", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 12, "title": "Consumption and expenditure on fidaxomicin and oral vancomycin for Clostridioides difficile infection: A 12-year longitudinal study of 43 countries and regions - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0924857925002195", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 13, "title": "My Treatment Approach to Clostridioides difficile Infection", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0025619621002639", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 14, "title": "Approach to Clostridioides difficile diarrheal infection - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S2950590925000204", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 15, "title": "Clinician Management Preferences for Clostridioides difficile Infection in Adults: A 2024 Emerging Infections Network Survey | Open Forum Infectious Diseases | Oxford Academic", "detail": "academic.oup.com", "url": "https://academic.oup.com/ofid/article/12/7/ofaf335/8165984", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 16, "title": "Review Management of Clostridioides difficile Infection: Diagnosis ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0002934324001670", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 17, "title": "SHEA/IDSA 2021 Clinical Practice Guideline Update for the Management of Clostridioides difficile Infection in Adults", "detail": "www.idsociety.org", "url": "https://www.idsociety.org/practice-guideline/clostridioides-difficile-2021-focused-update#idsa-main-nav", "authors": "www.idsociety.org", "host": "www.idsociety.org" }, { "number": 18, "title": "Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780550", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 19, "title": "Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines - PubMed", "detail": "www.ncbi.nlm.nih.gov", "url": "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=36441203&dopt=Abstract", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 20, "title": "Navigating the 2021 update to the IDSA/SHEA Clostridioides difficile guidelines: An ethical approach to equitable patient care - PMC", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726573", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 21, "title": "AGA Clinical Practice Guideline on Fecal Microbiota-Based ...", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S0016-5085(24)00041-6/pdf", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org" }, { "number": 22, "title": "[PDF] Advice on the designation of antimicrobials or groups of", "detail": "www.ema.europa.eu", "url": "https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/advice-designation-antimicrobials-or-groups-antimicrobials-reserved-treatment-certain-infections-humans-relation-implementing-measures-under-article-375-regulation-eu-20196-veterinary-medicinal_en.pdf", "authors": "www.ema.europa.eu", "host": "www.ema.europa.eu" }, { "number": 23, "title": "AGA Clinical Practice Update on Management of Clostridioides ...", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S0016-5085(26)00245-3/abstract", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org" }, { "number": 24, "title": "Clostridioides difficile Infection in Children: Recent Updates on ...", "detail": "publications.aap.org", "url": "https://publications.aap.org/pediatrics/article/152/3/e2023062307/193288/Clostridioides-difficile-Infection-in-Children", "authors": "publications.aap.org", "host": "publications.aap.org" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "Clostridioides difficile-associated disease - Management Approach | BMJ Best Practice", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-gb/230/management-approach", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com", "snippet": "Title: Clostridioides difficile-associated disease - Management Approach | BMJ Best Practice\n# Clostridioides difficile-associated disease. The main goal of treatment is to discontinue the implicated antimicrobial agent and begin appropriate therapy. All patients not already hospitalised should be a", "score": 0.93511593 }, { "number": 2, "title": "Clostridioides difficile-associated disease - Treatment algorithm | BMJ Best Practice", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-gb/230/treatment-algorithm", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com", "snippet": "Title: Clostridioides difficile-associated disease - Treatment algorithm | BMJ Best Practice\n# Clostridioides difficile-associated disease. Treatment recommendations are specific to patient groups: see disclaimer. #### initial episode: non-severe. 1st line – oral fidaxomicin or vancomycin or metro", "score": 0.8512743 }, { "number": 3, "title": "Discordant Clostridioides difficile diagnostic assay and treatment ...", "detail": "bmjopen.bmj.com", "url": "https://bmjopen.bmj.com/content/bmjopen/10/9/e036342.full.pdf", "authors": "bmjopen.bmj.com", "host": "bmjopen.bmj.com", "snippet": "the EIA negative result may be interpreted either as a false-­ negative or a toxin level below threshold in the case of a patient effectively presenting with CDI or as a true negative in the case of C. difficile toxigenic strain carriage. A third-­ stage test, either NAAT, toxigenic culture or GDH, ", "score": 0.7458619 }, { "number": 4, "title": "Discordant Clostridioides difficile diagnostic assay and treatment practice: a cross-sectional study in a tertiary care hospital, Geneva, Switzerland | BMJ Open", "detail": "bmjopen.bmj.com", "url": "https://bmjopen.bmj.com/content/10/9/e036342", "authors": "bmjopen.bmj.com", "host": "bmjopen.bmj.com", "snippet": "CDI diagnosis relies on the association of clinical manifestations and microbiological tests documenting the presence of a toxigenic C. difficile strain and toxin/s in stools.10 Symptomatic patients with both tests positive (NAAT+ or GDH+/EIA+) are likely to suffer from CDI. In the presence of disco", "score": 0.6937432 }, { "number": 5, "title": "Discordant Clostridioides difficile diagnostic assay and ... - BMJ Open", "detail": "bmjopen.bmj.com", "url": "https://bmjopen.bmj.com/content/10/9/e036342.reviewer-comments", "authors": "bmjopen.bmj.com", "host": "bmjopen.bmj.com", "snippet": "GENERAL COMMENTS. This study used retrospective data to investigate the treatment of patients with discordant C. difficile test results (NAAT positive/toxin.", "score": 0.4808937 }, { "number": 6, "title": "Effective treatment of Clostridioides difficile infection improves survival and affects graft-versus-host disease: a multicenter study by the Polish Adult Leukemia Group | Scientific Reports", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41598-024-56336-3", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "(2017).\"). This was reiterated in the 2021 update of IDSA/SHEA recommendations and the first practice guidelines for CDI management in HCT recipients of the American Society for Transplantation and Cellular Therapy (ASCTC) published in 202215 and Society for Healthcare Epidemiology of America (SHEA)", "score": 0.7393665 }, { "number": 7, "title": "Experimental glycopeptide antibiotic EVG7 prevents recurrent Clostridioides difficile infection by sparing members of the Lachnospiraceae family | Nature Communications", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41467-025-64067-w", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Despite contributing to the onset of CDI, antibiotics remain the standard of care treatment for CDI, typically as a 10-day course of oral vancomycin or fidaxomicin9 and Society for Healthcare Epidemiology of America (SHEA). Clin. Infect. Dis. 66, 987–994 (2018).\"),10 and Society for Healthcare Epide", "score": 0.7147281 }, { "number": 8, "title": "Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of Clostridioides difficile infection - An observational cohort study", "detail": "www.cell.com", "url": "https://www.cell.com/heliyon/fulltext/S2405-8440(24)06773-2", "authors": "www.cell.com", "host": "www.cell.com", "snippet": "Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of Clostridioides difficile infection - An observational cohort study: Heliyon. Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of _Clostridioides difficile_ infectio", "score": 0.70531887 }, { "number": 9, "title": "Experimental human colonisation with non-toxigenic Clostridioides difficile: a placebo-controlled randomised clinical trial | Nature Communications", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41467-026-74327-y", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "van Prehn, J. et al. European society of clinical microbiology and infectious diseases: 2021 update on the treatment guidance document for clostridioides difficile infection in adults. Clin. Microbiol. Infect. 27, S1–S21 (2021).\n\nArticle \nPubMed \nGoogle Scholar\n\nJohnson, S. et al. Clinical Practice ", "score": 0.7018975 }, { "number": 10, "title": "Plasmid-mediated metronidazole resistance in Clostridioides difficile | Nature Communications", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41467-020-14382-1", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "RT002, RT014/020, and RT078 are frequently reported in both Europe and the United States7.\"),8.\"). Metronidazole is used for the treatment of mild-to-moderate infections and vancomycin for severe infections, though vancomycin is increasingly indicated as a general first-line treatment9.\"),10.\"),11 d", "score": 0.54361504 }, { "number": 11, "title": "Retrospective Assessment of Guideline Adherence and Treatment Outcomes From Clostridioides difficile Infection Following the IDSA 2021 Clinical Guideline Update: Clostridioides difficile Infection | Open Forum Infectious Diseases | Oxford Academic", "detail": "academic.oup.com", "url": "https://academic.oup.com/ofid/article/11/10/ofae524/7758543", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "Title: Retrospective Assessment of Guideline Adherence and Treatment Outcomes From Clostridioides difficile Infection Following the IDSA 2021 Clinical Guideline Update: Clostridioides difficile Infection | Open Forum Infectious Diseases | Oxford Academic\nErik R Dubberke, Qinghua Li, Engels N Obi, Vl", "score": 0.9205687 }, { "number": 12, "title": "Consumption and expenditure on fidaxomicin and oral vancomycin for Clostridioides difficile infection: A 12-year longitudinal study of 43 countries and regions - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0924857925002195", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "### PloS One\n\n### Incidence, attributable mortality, and healthcare and out-of-pocket costs of clostridioides difficile infection in US medicare advantage enrollees\n\n### Clin Infect Dis\n\n### Burden of Clostridioides difficile infection (CDI)-a systematic review of the epidemiology of primary and rec", "score": 0.6836946 }, { "number": 13, "title": "My Treatment Approach to Clostridioides difficile Infection", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0025619621002639", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Cost permitting, I treat a first episode of _C difficile_ infection preferably with fidaxomicin over vancomycin but not metronidazole. The most common complication after _C difficile_ infection is recurrence. I manage a first recurrence with a vancomycin taper and pulse or fidaxomicin and recommend ", "score": 0.82795376 }, { "number": 14, "title": "Approach to Clostridioides difficile diarrheal infection - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S2950590925000204", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Most treatment guidelines currently recommend fidaxomicin or vancomycin for initial non-fulminant CDI for 10 days. use a 4-6 week pulse and taper regimen of", "score": 0.79637206 }, { "number": 15, "title": "Clinician Management Preferences for Clostridioides difficile Infection in Adults: A 2024 Emerging Infections Network Survey | Open Forum Infectious Diseases | Oxford Academic", "detail": "academic.oup.com", "url": "https://academic.oup.com/ofid/article/12/7/ofaf335/8165984", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "The 2021 Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) guidelines for *Clostridioides difficile* infection (CDI) introduced new recommendations for managing initial and recurrent CDI. Significant barriers, including high costs, insurance chal", "score": 0.76152116 }, { "number": 16, "title": "Review Management of Clostridioides difficile Infection: Diagnosis ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0002934324001670", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Under a Creative Commons license\n\nOpen access\n\n## Abstract\n\n_Clostridioides difficile_ infection is the most common healthcare-associated infection in the United States, with potential life-threatening complications and a significant impact on the costs of care. Antibiotic stewardship as well as dis", "score": 0.74161834 }, { "number": 17, "title": "SHEA/IDSA 2021 Clinical Practice Guideline Update for the Management of Clostridioides difficile Infection in Adults", "detail": "www.idsociety.org", "url": "https://www.idsociety.org/practice-guideline/clostridioides-difficile-2021-focused-update#idsa-main-nav", "authors": "www.idsociety.org", "host": "www.idsociety.org", "snippet": "The previous iteration of the treatment guidelines recommended either vancomycin or fidaxomicin for treatment of an initial CDI episode for both nonsevere and severe (but not fulminant) disease . Either drug was preferred over metronidazole, and this was a strong recommendation. With the additional ", "score": 0.902687 }, { "number": 18, "title": "Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780550", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "Updated IDSA/SHEA and ESCMID guidelines now reflect the increased efficacy of fidaxomicin in preventing recurrence and have both promoted fidaxomicin to first-line therapy with an initial CDI episode in both non-severe and severe disease and endorsed the role of bezlotoxumab in the prevention of rec", "score": 0.89121616 }, { "number": 19, "title": "Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines - PubMed", "detail": "www.ncbi.nlm.nih.gov", "url": "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=36441203&dopt=Abstract", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "Title: Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines - PubMed\nAn official website of the United States government. **The .gov means it’s official.**. Federal government websites o", "score": 0.890761 }, { "number": 20, "title": "Navigating the 2021 update to the IDSA/SHEA Clostridioides difficile guidelines: An ethical approach to equitable patient care - PMC", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726573", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "## Abstract\n\nThe 2021 focused update to the Infections Diseases Society of America/Society for Healthcare Epidemiology of America (IDSA/SHEA) guidelines for management of Clostridioides difficile infection (CDI) prioritizes the use of fidaxomicin over vancomycin for the treatment of initial and recu", "score": 0.8325776 }, { "number": 21, "title": "AGA Clinical Practice Guideline on Fecal Microbiota-Based ...", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S0016-5085(24)00041-6/pdf", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org", "snippet": "ACG Clinical · guidelines: prevention, diagnosis, and treatment of · Clostridioides difficile infections. Am J Gastroenterol · 2021;116:1124–", "score": 0.6768127 }, { "number": 22, "title": "[PDF] Advice on the designation of antimicrobials or groups of", "detail": "www.ema.europa.eu", "url": "https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/advice-designation-antimicrobials-or-groups-antimicrobials-reserved-treatment-certain-infections-humans-relation-implementing-measures-under-article-375-regulation-eu-20196-veterinary-medicinal_en.pdf", "authors": "www.ema.europa.eu", "host": "www.ema.europa.eu", "snippet": "abscesses associated with Rhodococcus equi. J Vet Intern Med, 2013. 27(1): p. 171-6. 345. Ettinger, S., Textbook of veterinary internal medicine : diseases of the dog and the cat, 8th edition. 2018: Elsevier, Philadelphia. 346. Möstl, K., et al., Something old, something new: update of the 2009 and ", "score": 0.66308063 }, { "number": 23, "title": "AGA Clinical Practice Update on Management of Clostridioides ...", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S0016-5085(26)00245-3/abstract", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org", "snippet": "2021 focused update guidelines on management of Clostridioides difficile infection in adults Clin Infect Dis.", "score": 0.65861565 }, { "number": 24, "title": "Clostridioides difficile Infection in Children: Recent Updates on ...", "detail": "publications.aap.org", "url": "https://publications.aap.org/pediatrics/article/152/3/e2023062307/193288/Clostridioides-difficile-Infection-in-Children", "authors": "publications.aap.org", "host": "publications.aap.org", "snippet": "FIGURE 3\n\nFIGURE 3 Refer to the image caption for details.\n\nView largeDownload slide\n\nA laboratory testing approach for diagnosis of Clostridioides difficile infection in children.a\n\naBased on the 2017 IDSA and SHEA guideline, which recommends a 2-step algorithm, including s stool toxin test (ie, gl", "score": 0.75312227 } ], "publishedAt": "2026-09-15T22:10:58.519135+00:00", "updatedAt": "2026-09-15T22:10:58.519135+00:00", "readingMinutes": 6, "slug": "clostridioides-difficile-treatment-selection" }